Ezad Saad M, McEntegart Margaret, Dodd Matthew, Didagelos Matthaios, Sidik Novalia, Li Kam Wa Matthew, Morgan Holly P, Pavlidis Antonis, Weerackody Roshan, Walsh Simon J, Spratt James C, Strange Julian, Ludman Peter, Chiribiri Amedeo, Clayton Tim, Petrie Mark C, O'Kane Peter, Perera Divaka
British Heart Foundation Centre of Research Excellence at the School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, United Kingdom.
West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, United Kingdom; Columbia University Medical Center, New York, New York, USA.
J Am Coll Cardiol. 2024 Jul 23;84(4):340-350. doi: 10.1016/j.jacc.2024.04.043. Epub 2024 May 15.
Complete revascularization of coronary artery disease has been linked to improved outcomes in patients with preserved left ventricular (LV) function.
This study sought to identify the impact of complete revascularization in patients with severe LV dysfunction.
Patients enrolled in the REVIVED-BCIS2 (Revascularization for Ischemic Ventricular Dysfunction) trial were eligible if baseline/procedural angiograms and viability studies were available for analysis by independent core laboratories. Anatomical and viability-guided completeness of revascularization were measured by the coronary and myocardial revascularization indices (RI and RI), respectively, where RI = (change in British Cardiovascular Intervention Society Jeopardy score [BCIS-JS]) / (baseline BCIS-JS) and RI= (number of revascularized viable segments) / (number of viable segments supplied by diseased vessels). The percutaneous coronary intervention (PCI) group was classified as having complete or incomplete revascularization by median RI and RI. The primary outcome was death or hospitalization for heart failure.
Of 700 randomized patients, 670 were included. The baseline BCIS-JS and SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) scores were 8 (Q1-Q3: 6-10) and 22 (Q1-Q3: 15-29), respectively. In those patients assigned to PCI, median RI and RI values were 67% and 85%, respectively. Compared with the group assigned to optimal medical therapy alone, there was no difference in the likelihood of the primary outcome in those patients receiving complete anatomical or viability-guided revascularization (HR: 0.90; 95% CI: 0.62-1.32; and HR: 0.95; 95% CI: 0.66-1.35, respectively). A sensitivity analysis by residual SYNTAX score showed no association with outcome.
In patients with severe LV dysfunction, neither complete anatomical nor viability-guided revascularization was associated with improved event-free survival compared with incomplete revascularization or treatment with medical therapy alone. (Revascularization for Ischemic Ventricular Dysfunction) [REVIVED-BCIS2]; NCT01920048).
冠状动脉疾病的完全血运重建与左心室(LV)功能保留患者的预后改善相关。
本研究旨在确定完全血运重建对严重LV功能障碍患者的影响。
如果独立核心实验室可获得基线/手术血管造影和存活心肌研究以供分析,则纳入REVIVED-BCIS2(缺血性心室功能障碍血运重建)试验的患者符合条件。血运重建的解剖学和存活心肌引导完整性分别通过冠状动脉和心肌血运重建指数(RI和RI)来衡量,其中RI =(英国心血管介入学会危险评分[BCIS-JS]的变化)/(基线BCIS-JS),RI =(血运重建的存活节段数)/(病变血管供应的存活节段数)。经皮冠状动脉介入治疗(PCI)组根据RI和RI的中位数分为完全或不完全血运重建。主要结局是死亡或因心力衰竭住院。
在700例随机分组的患者中,纳入了670例。基线BCIS-JS和SYNTAX(紫杉醇洗脱支架与心脏手术协同作用)评分分别为8(第一四分位数-第三四分位数:6-10)和22(第一四分位数-第三四分位数:15-29)。在分配接受PCI的患者中,RI和RI的中位数分别为67%和85%。与仅接受最佳药物治疗的组相比,接受完全解剖学或存活心肌引导血运重建的患者发生主要结局的可能性没有差异(HR:0.90;95%CI:0.62-1.32;以及HR:0.95;95%CI:0.66-1.35)。根据残余SYNTAX评分进行的敏感性分析显示与结局无关。
在严重LV功能障碍患者中,与不完全血运重建或仅接受药物治疗相比,完全解剖学或存活心肌引导血运重建均未与无事件生存期改善相关。(缺血性心室功能障碍血运重建)[REVIVED-BCIS2];NCT01920048)